Cougar Biotechnology, Inc.
Home | Careers | Contact | Site Map
Cougar Biotechnology, Inc.CompanyNewsLicensingResearch and DevelopmentInvestor Relations
Analyst Coverage Events Media SEC Filings Investor FAQs
Investor Relations

Cougar Biotechnology, Inc. is a Los Angeles-based publicly traded biotechnology company established to in-license and develop clinical stage drugs, with a specific focus on the field of oncology. Cougar's oncology portfolio includes CB7630, which is currently being tested in Phase II clinical trials in prostate cancer; CB3304, which is currently in a Phase I/II trial in multiple myeloma; and CB1089, which has been clinically tested in a number of solid tumor types.

On February 8, 2007, Cougar began trading on the OTC Bulletin Board® under the symbol "CGRB.OB." Cougar's common stock was approved for listing on The NASDAQ Global Market and began trading on NASDAQ under the symbol "CGRB" on December 7, 2007.

Cougar Biotechnology (NASDAQ: CGRB) .
Last Price Change Open Day High
()

Volume Previous Close Day Low


Cougar Biotechnology, Inc.
10990 Wilshire Blvd, Suite 1200
Los Angeles, CA 90024
(310) 943-8040 Main
(310) 943-8059 Fax